Compare CRTO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | ACHV |
|---|---|---|
| Founded | 2005 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.3M | 726.5M |
| IPO Year | 2013 | 2018 |
| Metric | CRTO | ACHV |
|---|---|---|
| Price | $15.21 | $7.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $34.00 | $13.83 |
| AVG Volume (30 Days) | 199.5K | ★ 1.4M |
| Earning Date | 05-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,296,692,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | $42.41 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.26 | $2.62 |
| 52 Week High | $25.29 | $8.64 |
| Indicator | CRTO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 28.02 | 53.53 |
| Support Level | N/A | $7.01 |
| Resistance Level | $19.85 | $8.56 |
| Average True Range (ATR) | 0.44 | 0.36 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 7.91 | 62.91 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.